CMCの翻訳サンプル

1.Purpose

The purpose of the present study, is to examine the effect of sodium zirconium cyclosilicate hydrate  (Brand name: Lokelma) on the treatment of pre-dialysis hyperkalemia in patients with poorly controlled serum potassium levels and undergoing chronic hemodialysis at least three times a week, this study is conducted in comparison with a control polystyrene sulfonate (brand name: Argamate jelly, argamate granules, kalimate dry syrup , kalimate oral solution, and kalimate powder) using the randomized controlled trial (RCT) data.

2.Background and grounds for scientific rationality

2.1.Background

Hyperkalemia is a serious condition that is directly linked with death from cardiac arrhythmia. In hemodialysis patients, the reports suggest that the pre-dialysis serum potassium level of ≥ 5.6 mEq/L is associated with death (all deaths, and cardiac death). These patients primarily depend on hemodialysis to maintain normal serum potassium levels due to a large decrease in or complete loss of their kidneys’ ability to excrete potassium. However, when treated with hemodialysis alone, many patients exhibit persistently high pre-dialysis serum potassium levels, which poses an urgent problem. Dialysis patients need to have an adequate intake of protein to maintain their nutritional status, taking into account the loss of proteins through dialysis.

1.Purpose

The purpose of the present study by randomized controlled trial (RCT) (active drug parallel group comparison study, superiority trial) is to examine the effect of sodium zirconium cyclosilicate hydrate (Brand name: Lokelma) on improving pre-dialysis hyperkalemia in comparison with polustyrene sulfonate (brand name: Argamate jelly, argamate granules, kalimate dry syrup, kalimate oral solution, and kalimate powder) as a control in patients with poorly controlled pre-dialysis poor control of serum potassium levels among those receiving chronic hemodialysis three times per week. The purpose of the present study, is to examine the effect of sodium zirconium cyclosilicate hydrate effect (Brand name: Lokelma) on the treatment of pre-dialysis hyperkalemia in patientpatients with poorly controlled serum potassium levels and undergoing chronic haemodialysishemodialysis1  at least three times a week, this study is conducted in comparison with a control polustyrenepolystyrene2  sulfonate (brand name: Argamate jelly, argamate granules, kalimate dry syrup , kalimate oral solution, and kalimate powder) using the randomized controlled trial (RCT) data.3 

2.Background and grounds for scientific rationality

2.1.Background

Hyperkalemia is a serious condition that can directly causeis directly linked with death from cardiac 4 arrhythmia and cardiac death5 . In hemodialysis patients, a relationship betweenthe reports suggest that the pre-dialysis serum potassium level of ≥ 5.6 mEq/L is associated and with death (all deaths, and cardiac death) has been reported6 . HemodialysisThese7  patients primarily depend on hemodialysis to maintain normal serum potassium levels due to a large drop in,decrease in or complete or loss 8 of their kidneys’ kidney’s ability to excrete potassium 9 . However, when treated with hemodialysis alone, many patients exhibit persistently high pre-dialysis serum potassium levels, which poses an urgent problem. Dialysis patients need to have an adequate intake of protein to maintain their nutritional status, taking into account the10 Considering loss of proteins through dialysis, the amount of protein intake to maintain nutritional status needs to be ensured in dialysis patients.